-
公开(公告)号:US20250134858A1
公开(公告)日:2025-05-01
申请号:US18836268
申请日:2023-02-10
Applicant: EpicentRx, Inc.
Inventor: Scott CAROEN , Tony REID , Bryan ORONSKY
IPC: A61K31/397 , A61K31/155 , A61K31/355 , A61K31/465 , A61K31/616 , A61K31/7088 , A61K35/14 , A61K35/18 , A61K36/062 , A61K39/395 , A61K45/06 , A61P1/16
Abstract: Compositions and methods for preventing or treating a disease or a disorder associated with dyslipidemia are provided. This includes prevention or treatment of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH). The method comprises administering an effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, to the subject in need thereof to reduce at least one factor of the disease or the disorder, such as a hepatic steatosis score, a serum ALT level, a fibrosis marker, a serum AST level, a hepatic level of cholesterol, a hepatic level of triglycerides, insulin resistance, hyperinsulinemia, a serum NLRP3 level, an oxidative or inflammatory stress marker in the subject, and/or a marker associated with low-density lipoprotein (LDL). In some embodiments, the effective amount of RRx-001, or the pharmaceutically acceptable salt thereof, is administered in a pharmaceutical composition that includes a blood product and/or an agent.
-
公开(公告)号:US12280123B2
公开(公告)日:2025-04-22
申请号:US17575488
申请日:2022-01-13
Applicant: EpicentRx, Inc.
Inventor: Christopher Larson , Bryan Oronsky , Tony R. Reid
IPC: A61K35/761 , A61K47/68 , A61K47/69 , A61K48/00 , A61P35/00 , C12N7/02 , C12N7/04 , C12N15/62 , C12N15/85 , C12N15/86
Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.
-
公开(公告)号:US20240374562A1
公开(公告)日:2024-11-14
申请号:US18182153
申请日:2023-03-10
Applicant: EpicentRx, Inc.
Inventor: Bryan T. ORONSKY , Jan SCICINSKI , Susan KNOX , William FITCH , Frans A. KUYPERS , Marcel FENS , Sandra LARKIN , Pedro CABRALES , Chad BROUSE
IPC: A61K31/397 , A01N1/02 , A61K31/12 , A61K31/16 , A61K31/198 , A61K31/215 , A61K31/22 , A61K31/255 , A61K31/40 , A61K31/445 , A61K33/00 , A61K35/14 , A61K35/16 , A61K35/18 , A61K38/17 , A61K45/06 , A61K47/64 , A61N5/10
Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
-
公开(公告)号:US12036247B2
公开(公告)日:2024-07-16
申请号:US16604675
申请日:2018-04-12
Applicant: EpicentRx, Inc.
Inventor: Tony R. Reid , Christopher Larson , Bryan T. Oronsky
IPC: A61P35/00 , A61K35/74 , A61K35/768 , A61K48/00 , C07K14/54 , C12N9/64 , C12N15/86 , C12N15/861
CPC classification number: A61K35/74 , A61K35/768 , A61K48/00 , A61P35/00 , C12N9/6454 , C12N15/86 , C12N15/861 , C07K2319/50 , C12N2710/10343 , C12Y304/21075
Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.
-
公开(公告)号:US20210178050A1
公开(公告)日:2021-06-17
申请号:US17119423
申请日:2020-12-11
Applicant: EpicentRx, Inc.
Inventor: Bryan T. Oronsky , Scott Caroen
Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.
-
公开(公告)号:US20200254016A1
公开(公告)日:2020-08-13
申请号:US16629099
申请日:2018-07-06
Applicant: EpicentRx, Inc.
Inventor: Bryan T. Oronsky
IPC: A61K35/16 , A61K31/337 , A61K31/407 , A61K31/4745 , A61K31/675 , A61K31/7042 , A61K31/704 , A61K31/282 , A61K35/15 , A61K47/46 , A61P35/00
Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.
-
公开(公告)号:US20200223901A1
公开(公告)日:2020-07-16
申请号:US16651079
申请日:2018-09-27
Applicant: EpicentRx, Inc.
Inventor: Christopher Larson , Tony R. Reid , Bryan T. Oronsky
IPC: C07K14/715 , C07K14/54 , C12N15/62 , A61P35/00
Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
-
公开(公告)号:US20200046682A1
公开(公告)日:2020-02-13
申请号:US16353047
申请日:2019-03-14
Applicant: EpicentRx, Inc. , Northrop Grumman Innovation Systems, Inc.
Inventor: Mark D. Bednarski , Susan Knox , Louis Cannizzo , Kirstin Warner , Robert Wardle , Stephen Velarde , Shoucheng Ning
IPC: A61K31/397 , A61K9/00 , A61N5/10 , C07D205/04
Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
-
公开(公告)号:US20200032223A1
公开(公告)日:2020-01-30
申请号:US16604194
申请日:2018-04-10
Applicant: EpicentRx, Inc.
Inventor: Tony R. Reid , Bryan T. Oronsky , Christopher Larson
IPC: C12N7/00
Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.
-
公开(公告)号:US10342778B1
公开(公告)日:2019-07-09
申请号:US15298735
申请日:2016-10-20
Applicant: EpicentRx, Inc.
Inventor: Bryan T. Oronsky , Jan Scicinski
IPC: A61N5/10 , A61K31/397 , A61K9/00 , A61K31/495
Abstract: The invention provides therapeutic methods and kits for treating brain metastases using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and optionally an additional anti-cancer agent.
-
-
-
-
-
-
-
-
-